Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 86

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 86
---
 Common StockholdersImpact per ShareReported$939 $183 $755 $(0)$755 $0.51 Non-GAAP adjustments:Amortization expense225 31 194 2 191 0.13 Goodwill and other intangible asset impairment charges0 00—00.00 Acquisition/divestiture-related net charges (credits)99 495—950.06 Restructuring and restructuring-related net charges (credits)36 630—300.02 Investment portfolio net losses (gains) and impairments(6)(1)(5)—(5)(0.00)European Union (EU) Medical device regulation (MDR) implementation costs11 29—90.01 Deferred tax expenses (benefits)— (47)47—470.03 Discrete tax items— (1)1—10.00 Adjusted$1,303 $177 $1,126 $2 $1,124 $0.75 

 Three Months Ended September 30, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$669 $200 $468 $(0)$469 $0.32 Non-GAAP adjustments:Amortization expense205 28 177 2 175 0.12 Acquisition/divestiture-related net charges (credits)144 (56)200 — 200 0.13 Restructuring and restructuring-related net charges (credits)52 7 45 — 45 0.03 Investment portfolio net losses (gains) and impairments(1)0 (1)— (1)(0.00)EU MDR implementation costs13 2 12 — 12 0.01 Deferred tax expenses (benefits)— (38)38 — 38 0.03 Adjusted$1,082 $143 $939 $2 $937 $0.63 

41

Table of Contents

Nine Months Ended September 30, 2025

Our net sales for the first nine months of 2025 were $14.788 billion, compared to $12.186 billion